Streetbeat News

AMIX

Autonomix Medical Inc.

Industry

Surgical and Medical Instrument Manufacturing

Open

9.52

Mkt cap

13M

Volume

150K

High

11.69

P/E Ratio

-0.59

52-wk high

152.00

Low

9.52

Div yield

N/A

52-wk low

7.51

Autonomix Medical, Inc. (NASDAQ:AMIX) stock surged 106% on Monday due to promising preliminary results from its proof-of-concept trial for a new pain management technology. The trial showed significant pain reduction in patients with pancreatic cancer pain using femoral access, leading to the elimination of opioid use in responding patients.

Portfolio Pulse from Vandana Singh

October 28, 2024 | 3:08 pm

U.S. stocks rose on Monday, with the Dow Jones gaining over 300 points. ON Semiconductor reported better-than-expected earnings, despite a revenue decline. Healthcare Triangle, Autonomix Medical, and Evoke Pharma saw significant stock price increases, while SMX, Sonnet BioTherapeutics, and Upexi experienced declines.

Portfolio Pulse from Avi Kapoor

October 28, 2024 | 1:59 pm

Autonomix Medical shares have resumed trading after a temporary halt. The resumption of trading could indicate a resolution of any issues that led to the halt, potentially impacting investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 1:48 pm

Autonomix Medical shares experienced a volatile trading session, initially resuming trading and then being halted to the downside. Despite this, the stock is up 146.04%.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 1:39 pm

Autonomix Medical shares have been halted due to a significant upside movement, with the stock now up by 173.28%.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 1:32 pm

Autonomix Medical shares rose following positive preliminary results from a clinical trial of its RF Ablation technology, showing 100% of the responder group eliminated opioid use and reduced pain scores.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 12:20 pm

Autonomix has reported preliminary results from its clinical trial of RF ablation technology, showing significant success in eliminating opioid use and reducing pain scores among the responder group. The trial is expected to complete enrollment by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 12:01 pm

Trading has been halted for a company at 7:50:00 p.m. ET due to pending news. This could indicate significant upcoming announcements that may impact the stock price.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:50 pm

Autonomix Medical has announced a 1-for-20 reverse stock split, effective October 24, 2024. The company's common stock will begin trading on a post-split basis on October 25, reducing outstanding shares from 23 million to 1.15 million.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:32 pm

Autonomix Medical, Inc. (NASDAQ:AMIX) announced positive preliminary results from its clinical trial on nerve ablation for pancreatic cancer pain, showing potential in pain mitigation.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 11:02 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.